OncoCyte Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . OncoCyte Corp
OCX Stock  USD 2.52  0.11  4.18%   
OncoCyte Corp financial statements provide useful quarterly and yearly information to potential OncoCyte Corp investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on OncoCyte Corp financial statements helps investors assess OncoCyte Corp's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting OncoCyte Corp's valuation are summarized below:
Gross Profit
116 K
Market Capitalization
72.1 M
Enterprise Value Revenue
104.3918
Revenue
709 K
Earnings Share
(4.44)
We have found one hundred twenty available trending fundamental ratios for OncoCyte Corp, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to check out all of OncoCyte Corp recent market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road.

OncoCyte Corp Total Revenue

1.26 Million

Check OncoCyte Corp financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among OncoCyte Corp's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 M, Interest Expense of 56.8 K or Selling General Administrative of 11.2 M, as well as many indicators such as Price To Sales Ratio of 13.9, Dividend Yield of 0.0015 or PTB Ratio of 0.64. OncoCyte financial statements analysis is a perfect complement when working with OncoCyte Corp Valuation or Volatility modules.
  
Check out the analysis of OncoCyte Corp Correlation against competitors.
For more information on how to buy OncoCyte Stock please use our How to Invest in OncoCyte Corp guide.

OncoCyte Corp Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets49.1 M86.1 M40.7 M
Slightly volatile
Short and Long Term Debt Total4.1 M3.3 M3.6 M
Pretty Stable
Other Current Liabilities4.8 M6.4 M4 M
Slightly volatile
Total Current Liabilities7.6 M8.3 M6.6 M
Slightly volatile
Property Plant And Equipment Net3.8 M6.3 M3 M
Slightly volatile
Accounts Payable621.2 K1.1 M514.9 K
Slightly volatile
Cash12.8 M10.8 M9.5 M
Slightly volatile
Non Current Assets Total77.5 M73.8 M31 M
Slightly volatile
Non Currrent Assets Other1.5 M2.5 M1.3 M
Slightly volatile
Other Assets1.091.15885.9 K
Slightly volatile
Cash And Short Term Investments14.5 M10.8 M11.5 M
Slightly volatile
Common Stock Total Equity356.1 M339.2 M132 M
Slightly volatile
Common Stock Shares Outstanding9.2 M8.8 M3.1 M
Slightly volatile
Liabilities And Stockholders Equity49.1 M86.1 M40.7 M
Slightly volatile
Other Current Assets1.1 M899.3 K814.3 K
Slightly volatile
Total Liabilities59.5 M56.7 M25.1 M
Slightly volatile
Property Plant And Equipment Gross3.8 M6.3 M3 M
Slightly volatile
Total Current Assets15.7 M12.3 M12.5 M
Slightly volatile
Short Term Debt568.6 K598.5 K2 M
Slightly volatile
Intangible Assets68.3 M65.1 M25 M
Slightly volatile
Common Stock374.7 M356.8 M135.2 M
Slightly volatile
Property Plant Equipment10.3 M9.8 M3.7 M
Slightly volatile
Long Term Debt905.1 K1.7 M885.2 K
Slightly volatile
Short and Long Term Debt1 M1.5 M831.1 K
Slightly volatile
Long Term Debt Total1.2 M1.7 M940 K
Slightly volatile
Non Current Liabilities Total26.9 M48.4 M17.1 M
Slightly volatile
Capital Lease Obligations2.8 M3.3 M1.8 M
Slightly volatile
Net Invested Capital32 M23.5 M18.9 M
Slightly volatile
Net Working Capital3.8 M4 M6.5 M
Pretty Stable
Capital Stock222.7 M356.8 M149.5 M
Slightly volatile
Non Current Liabilities Other39.2 M45.9 M18 M
Slightly volatile
Other Liabilities46.1 M88.2 M27.7 M
Slightly volatile
Net Receivables528.8 K556.6 K453.2 K
Slightly volatile
Warrants4.2 M4.8 M5.2 M
Slightly volatile

OncoCyte Corp Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.4 M1.9 M1.1 M
Slightly volatile
Selling General Administrative11.2 M12.4 M8.6 M
Slightly volatile
Other Operating Expenses23.2 M30.6 M18.5 M
Slightly volatile
Research Development7.8 M10.7 M6.6 M
Slightly volatile
Total Operating Expenses22.1 M29.5 M17.7 M
Slightly volatile
Interest Income33.9 K35.6 K95.2 K
Very volatile
Selling And Marketing Expenses3.6 M3.2 M2.4 M
Slightly volatile
Reconciled Depreciation2.4 M3 M1.6 M
Slightly volatile
Non Recurring14.9 M16.8 M18.3 M
Slightly volatile

OncoCyte Corp Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation3.8 M7.6 M3.1 M
Slightly volatile
Begin Period Cash Flow28 M26.7 M11.6 M
Slightly volatile
Depreciation1.6 M1.9 M1.3 M
Slightly volatile
Capital Expenditures307 K323.1 K655 K
Slightly volatile
End Period Cash Flow13.8 M12.8 M10.3 M
Slightly volatile
Total Cash From Financing Activities27.8 M14 M21.3 M
Slightly volatile
Change To Netincome29 M27.7 M9.2 M
Slightly volatile
Issuance Of Capital Stock15.1 M15.9 M22 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio13.914.6494.9377
Slightly volatile
Dividend Yield0.00150.00170.0018
Slightly volatile
Days Sales Outstanding203106121
Slightly volatile
Stock Based Compensation To Revenue3.983.944.343
Pretty Stable
Capex To Depreciation0.140.150.4832
Pretty Stable
EV To Sales9.139.6193.5789
Slightly volatile
Inventory Turnover0.50.5318.7214
Slightly volatile
Days Of Inventory On Hand750714202
Slightly volatile
Payables Turnover1.751.031.7158
Pretty Stable
Sales General And Administrative To Revenue12.848.2212.8627
Pretty Stable
Research And Ddevelopement To Revenue4.735.577.1575
Slightly volatile
Capex To Revenue0.160.171.0273
Very volatile
Cash Per Share1.351.427.852
Slightly volatile
Days Payables Outstanding298367309
Pretty Stable
Income Quality0.50.760.5417
Slightly volatile
Intangibles To Total Assets0.710.680.3786
Slightly volatile
Current Ratio1.841.341.9718
Pretty Stable
Receivables Turnover4.113.575.1581
Slightly volatile
Graham Number18.0619.0139.3468
Slightly volatile
Capex Per Share0.03140.03310.1932
Pretty Stable
Revenue Per Share0.210.230.4146
Very volatile
Interest Debt Per Share0.420.444.1921
Slightly volatile
Debt To Assets0.04190.04410.2115
Slightly volatile
Operating Cycle100106165
Slightly volatile
Days Of Payables Outstanding298367309
Pretty Stable
Ebt Per Ebit0.860.891.0297
Very volatile
Long Term Debt To Capitalization0.04710.04960.124
Slightly volatile
Total Debt To Capitalization0.110.120.2948
Slightly volatile
Quick Ratio1.821.341.9583
Pretty Stable
Net Income Per E B T1.261.011.1952
Slightly volatile
Cash Ratio1.471.181.4379
Slightly volatile
Days Of Inventory Outstanding750714202
Slightly volatile
Days Of Sales Outstanding203106121
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.830.911.0184
Slightly volatile
Fixed Asset Turnover0.40.320.2526
Slightly volatile
Debt Ratio0.04190.04410.2115
Slightly volatile
Price Sales Ratio13.914.6494.9377
Slightly volatile
Asset Turnover0.02750.02310.0231
Pretty Stable

OncoCyte Fundamental Market Drivers

Cash And Short Term Investments9.4 M

OncoCyte Upcoming Events

29th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
29th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About OncoCyte Corp Financial Statements

OncoCyte Corp investors use historical fundamental indicators, such as OncoCyte Corp's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in OncoCyte Corp. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue5.9 M6.2 M
Total Revenue1.7 M1.3 M
Cost Of Revenue1.3 M1.5 M
Stock Based Compensation To Revenue 3.94  3.98 
Sales General And Administrative To Revenue 8.22  12.84 
Research And Ddevelopement To Revenue 5.57  4.73 
Capex To Revenue 0.17  0.16 
Revenue Per Share 0.23  0.21 
Ebit Per Revenue(15.05)(15.80)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
CRMSalesforce
CCitigroup
GMGeneral Motors

Additional Tools for OncoCyte Stock Analysis

When running OncoCyte Corp's price analysis, check to measure OncoCyte Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OncoCyte Corp is operating at the current time. Most of OncoCyte Corp's value examination focuses on studying past and present price action to predict the probability of OncoCyte Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OncoCyte Corp's price. Additionally, you may evaluate how the addition of OncoCyte Corp to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY